Twice-Monthly GLP-1 Shot Helps Manage Blood Sugar, Weight Loss in Trial

# Twice-Monthly GLP-1 Shot Helps Manage Blood Sugar, Weight Loss in Trial

A new clinical trial demonstrates that a twice-monthly GLP-1 injection effectively reduces blood sugar levels and promotes weight loss in people with type 2 diabetes. The extended dosing schedule offers a practical alternative to the weekly injections currently available on the market.

Researchers tested the longer-acting formulation in a randomized controlled trial, tracking improvements in glycemic control and body weight reduction. Participants receiving the biweekly injections showed substantial reductions in both blood glucose levels and body mass. The medication works by mimicking glucagon-like peptide-1, a hormone that regulates appetite and blood sugar.

The twice-monthly dosing interval addresses a common barrier to medication adherence. Weekly injections require more frequent self-administration, which some patients find burdensome. Reducing injection frequency to twice monthly simplifies the treatment regimen while maintaining therapeutic effectiveness.

GLP-1 receptor agonists, originally developed for diabetes management, have gained attention for their weight loss effects in people both with and without type 2 diabetes. This trial extends that evidence base by demonstrating that a lower-frequency formulation preserves the metabolic benefits of more frequent dosing.

The study measured standard diabetes markers alongside weight outcomes. Participants tolerated the medication well, with adverse effects typical of the GLP-1 drug class, including nausea and gastrointestinal symptoms that often diminish with continued use.

Healthcare providers have increasingly prescribed GLP-1 medications as first-line options for type 2 diabetes when lifestyle modifications alone prove insufficient. Extended dosing intervals could expand access by reducing injection-related barriers. Patients struggling with weekly schedules may find the biweekly approach more sustainable.

Researchers plan additional studies to evaluate long-term safety and effectiveness.